Invivo anti-Mouse IL-17F Recombinant mAb

IL-17F is an important member of the IL-17 cytokine family encoded by the IL-17F gene, primarily produced by immune cells including activated CD4⁺ T cells (particularly the Th17 cell subset), γδ T cells, innate lymphoid cells, and mast cells. The protein exists as a disulfide-linked homodimer and can also form heterodimers with IL-17A. Its structure contains a highly conserved cystine-knot motif, and upon binding to the IL-17 receptor complex on the cell surface (composed mainly of IL-17RA and IL-17RC heterodimers), it activates downstream NF-κB and MAPK signaling pathways, inducing the expression of various chemokines (such as CXCL1, CXCL8), pro-inflammatory cytokines (such as IL-6, TNF-α), and antimicrobial peptides. Under physiological conditions, IL-17F plays an important role in host defense at mucosal surfaces (particularly the respiratory and gastrointestinal tracts), assisting in the clearance of extracellular bacterial and fungal infections; however, under pathological conditions, overexpression of IL-17F is a core driving factor in various autoimmune and inflammatory diseases, including psoriasis, ankylosing spondylitis, inflammatory bowel disease, and asthma. Notably, although IL-17F and IL-17A are highly similar in structure and function (sharing approximately 50% sequence homology and utilizing the same receptor subunits), IL-17F generally exhibits weaker pro-inflammatory activity than IL-17A and is expressed at lower levels in vivo, with the two exhibiting complementarity and differences in function and regulatory mechanisms. Currently, specific antibodies targeting IL-17F (such as bimekizumab, a bispecific antibody that neutralizes both IL-17A and IL-17F) have demonstrated promising therapeutic prospects in clinical trials for psoriasis and ankylosing spondylitis, offering new treatment options for patients with autoimmune diseases.